The diabetes drug semaglutide, also known as Ozempic, has a positive effect on patients with chronic kidney disease and obesity. The amount of protein in their urine decreased, as did the degree of inflammation of their kidneys and their blood pressure.

Semaglutide outperformed 7 diabetes medications in reducing risk of Alzheimer's disease, according to a study of over 1 million patients with type 2 diabetes.

Semaglutide, the active ingredient in the diabetes and weight loss drugs Ozempic and Wegovy, could lower the risk for Alzheimer’s disease, a new study shows.